Activins were discovered and, in fact, named more than a quarter century ago based on their abilities to stimulate pituitary follicle-stimulating hormone (FSH) synthesis and secretion. However, it is only in the last decade that we have finally come to understand their underlying mechanisms of action in gonadotroph cells. In this minireview, we chronicle the research that led to the recent discovery of forkhead box L2 (FOXL2) as an essential mediator of activin-regulated FSH beta subunit (Fshb) transcription in vitro and in vivo.
Research between the 1930s and 1980s established that a nonsteroidal hormone, an inhibin, from the gonads could selectively suppress follicle-stimulating hormone (FSH) secretion from pituitary gonadotroph cells without affecting luteinizing hormone (LH) (e.g., [1] [2] [3] [4] [5] [6] [7] ). Three groups (led by Vale, Guillemin, and Robertson) subsequently isolated two proteins, inhibin A and inhibin B, from ovarian follicular fluid based on their abilities to suppress FSH secretion from rat pituitary cultures [8] [9] [10] . The inhibins share a common a subunit (inhibin a), disulfide linked to one of two structurally related b subunits (inhibin bA or bB). In the course of their investigations, the Vale and Guillemin groups made the serendipitous observation that other protein fractions possessed the opposite activity to those containing inhibins, that is, they stimulated FSH but not LH release from cultured pituitary cells [11, 12] . The subsequent purification of the associated proteins revealed homo-or heterodimers of the two inhibin b subunits; what we now call activins A, B, and AB. These seminal discoveries established inhibins and activins, members of the larger transforming growth factor b (TGFb) superfamily, as the yin and yang of selective FSH regulation.
Research in the 1990s uncovered basic mechanisms of signal transduction by activins and other TGFb ligands via receptor serine/threonine kinases and the homolog of Drosophila mothers against decapentaplegic (SMAD) effector proteins [13, 14] . In 2000, Vale and colleagues described a mechanism of inhibin action via competitive antagonism of activin receptor binding and signaling [15] . Though this discovery suggested that activins were the real drivers of the system, the link between activin receptor activation and FSH secretion was missing. Indeed, it is only in the last few years that we have finally begun to unravel the molecular details [16] [17] [18] . Here, we provide a brief historical overview of the research that, at last, shed some light on this long elusive process.
MECHANISTIC INSIGHT INTO FSH SYNTHESIS: OVERCOMING ROADBLOCKS
Like other members of the glycoprotein hormone family, FSH is a heterodimer produced via the noncovalent association of the common a gonadotropin subunit (often called aGSU and more recently chorionic gonadotropin a) and a hormonespecific b subunit (FSHb or FSHB). The b subunit confers biological specificity to the ligand, and its synthesis is generally regarded as rate limiting in the production of the mature hormone. Therefore, an understanding of activinregulated FSH synthesis and secretion necessarily starts with an analysis of Fshb/FSHB transcriptional regulation. Unfortunately, such analyses were hampered for at least a decade by two important roadblocks. First, gonadotrophs, the only pituitary cells that produce FSH, are relatively rare (5%-10% of the total cell population of the anterior pituitary gland). Second, for many years, a suitable homologous cell line was needed, but lacking. This latter obstacle was finally overcome with the development of the immortalized murine gonadotroph-like cell line, LbT2, by Mellon and colleagues [19] . The cells were derived from a pituitary tumor in a transgenic mouse expressing the SV40 large T antigen under the control of the rat LHb promoter. They express the LHb subunit as well as aGSU and other gonadotroph markers, including the gonadotropinreleasing hormone (GnRH) receptor and steroidogenic factor 1 (SF1 or NR5A1) [19] . Initial analyses, however, suggested that LbT2 cells were deficient in FSHb expression, representing another apparent roadblock to functional studies of FSH synthesis. Importantly, Low and colleagues discovered that LbT2 cells release FSH and produce Fshb mRNA, particularly when treated with activins [20] . This observation paved the way for mechanistic studies of FSH synthesis.
ACTIVIN REGULATION OF FSHB TRANSCRIPTION: CANONICAL SIGNALING
Within a few years of their discovery, data from several laboratories converged to show that activins stimulate both Fshb mRNA expression and stability [21] [22] [23] [24] [25] [26] . Moreover, activin B, a product of gonadotrophs, emerged as the likely endogenous form of the ligand regulating FSH synthesis [27] . Early attempts to delineate mechanisms of activin-stimulated Fshb transcription by transfecting Fshb promoter-reporters into mixed primary pituitary cultures and gonadotroph-like aT3-1 cells failed [21, 28, 29] . An important breakthrough came in 2001 when the Mellon and Miller laboratories showed that the proximal promoter (5 0 -flanking sequence) of the ovine Fshb gene conferred basal activity to a luciferase reporter in LbT2 cells, but not other cell lines [28] . Moreover, exogenous activin A further increased reporter activity, suggesting that activins regulate ovine Fshb transcription. Subsequent analyses showed that the rat, murine, and porcine proximal Fshb promoters similarly confer activin-induced reporter activity in these cells [29] [30] [31] [32] [33] [34] . Interestingly, though the human FSHB promoter responds robustly to GnRH, it is only weakly induced by activins in LbT2 cells [35] [36] [37] . Whether this reflects a true interspecies difference in activin sensitivity or rather limitations of this in vitro model to understand regulation of the human gene is presently unclear. However, it is notable that expression of a human FSHB minigene in gonadotrophs of transgenic mice requires sequences both 5 0 of the transcription start site and 3 0 of translation termination codon [38] . Regardless, as described in greater detail below (see The Story of the Pig and the FOX), an appreciation of interspecies differences in Fshb/ FSHB promoter-reporter activities in LbT2 cells led to an important advance in our understanding of activin-regulated Fshb transcription [32] .
As mentioned above, a generic mechanism of activinmediated signal transduction was previously described [13, 14] . This served as a point of departure for more in-depth and systematic analyses of activin-regulated Fshb expression (Fig.  1) . In general, dimeric activins bind complexes of type I/type II receptor serine/threonine kinases. Upon ligand binding, the type II receptors phosphorylate type I receptors, which in turn phosphorylate signaling proteins in the SMAD family, SMADs 2 and 3 in particular. These receptor-regulated SMADs partner with a cofactor, SMAD4, accumulate in the nucleus, and regulate target gene transcription. SMAD3 and SMAD4 (but not full-length SMAD2) can bind DNA directly via the minimal SMAD-binding element (SBE), GTCT or its reverse complement (AGAC) [39] [40] [41] . However, this element is common in the genome and binds SMADs with low affinity [42] . Specificity in SMAD activation of target genes therefore appears to come from partnership with cofactors, which bind cis-elements in close proximity to SBEs [43] .
Two activin type II receptors, ACVR2A and ACVR2B, have been described [44] [45] [46] . ACVR2A may be the more critical of the two for FSH production as Acvr2a knockout mice are FSH deficient [47] . Thus, even if present in gonadotrophs, ACVR2B does not appear to compensate for the loss of ACVR2A in vivo. Acvr2b knockout mice die postnatally because of cardiac and patterning defects [48] , precluding assessment of the receptor's role in FSH synthesis, at least using this animal model. Both ACVR2A and ACVR2B are expressed in LbT2 cells [28, 49, 50] , but their relative roles in mediating activin induction of Fshb transcription have not been reported. There are seven type I receptors (also called activin receptor-like kinases or ALKs) in the TGFb superfamily. Activin A appears to signal exclusively via ALK4 (also known as ACVR1B), whereas activin B can signal via both ALK4 and the related ALK7 (ACVR1C) [51, 52] . Female ALK7 (Acvr1c)-deficient mice have reduced FSH levels on diestrus, but this may reflect an indirect effect of the gene deletion in the ovary [53] ; not only do the ovaries of Acvr1c knockout mice show impaired responses to exogenous gonadotropins, but FSH release from their pituitaries in primary culture is normal, both basally and in response to exogenous activins. ALK4 (Acvr1b)-deficient mice die during embryonic development [54] ; therefore, the necessity for this receptor in FSH synthesis in vivo has not yet been established. A small molecule inhibitor of ALK4, ALK5, and ALK7 (SB431542; [55] ) abrogates activin-induced Fshb transcription in LbT2 cells [50, 56] , but the relative roles of the different receptors have not been reported. Constitutively active forms of ALK4 and ALK7 equivalently and robustly induce Fshb reporter activity when transfected into LbT2 cells [37, 51] . Additional studies in vitro and in vivo are needed to determine the relative contributions of the two receptors to activinregulated FSH synthesis. The recent development of conditional alleles for Acvr1b [57, 58] , allowing cell-specific gene deletion, should greatly facilitate such analyses in mice.
Using both overexpression and knockdown approaches, Woodruff and colleagues established a role for SMAD3, but not SMAD2, in activin induction of the rat Fshb promoter in LbT2 cells [33, 59] . Furthermore, they identified a canonical 8-bp SBE (GTCTAGAC; [60] ) (see Fig. 1 ) in the proximal promoter that is essential for full induction of rat Fshb reporter activity by activins. These data were independently corroborated by Kaiser and colleagues [31] , and both groups demonstrated synergistic stimulation of Fshb by SMAD3 and SMAD4 when the two proteins were overexpressed in LbT2 cells. Both activin-and SMAD-dependent induction of murine Fshb reporter activity depend upon a comparable SBE [35, 61] . In contrast to the rat promoter, SMAD2, in addition to SMAD3, appears to play a role in activin induction of murine Fshb [29, 62] . Indeed, activin A stimulates the formation of SMAD2-SMAD3-SMAD4 complexes that can bind the 8-bp SBE in the murine promoter [35] . SMAD4 is absolutely required for activin A induction of the murine Fshb transcription in LbT2 cells and must bind DNA to mediate its effects [63] .
At present, there are few published data that speak to the relative roles of SMAD proteins in FSH synthesis in vivo. In one model of Smad3 deficiency in mice, adult males exhibit a 30% reduction in pituitary Fshb mRNA levels [64] . However, Lhb mRNA levels are suppressed to a similar extent, so it is not clear whether the effect of the gene deletion is specific to activin signaling or reflects a more general impairment in gonadotroph function or development (though see [64, 65] ). In females of the same strain (in which exon 8 of the gene is deleted), serum FSH, but not LH, levels are increased [66] . However, these females are infertile and show clear deficits in ovarian function [67] . These data suggest that SMAD3 alone may be not required for FSH synthesis in vivo, but its specific role in activin-regulated FSH synthesis at the level of the gonadotroph has not been reported. Interestingly, females from a second Smad3-deficient model (in which exon 2 is deleted) are subfertile [68] , suggesting that existing Smad3 knockout models might not completely ablate the SMAD3 protein and/or might alter SMAD3 function in different ways. Global Smad2 [69] and Smad4 [70, 71] knockout mice die during embryonic development, precluding an assessment of SMAD2 or SMAD4's roles in fertility, in general, and FSH synthesis, in particular. Conditional (floxed) alleles for Smad2 [72] , Smad3 [73] , and Smad4 [74] [75] [76] have been developed, which should enable an assessment of their relative roles in FSH production in gonadotrophs, at least in mice.
As described above, the human FSHB promoter responds only weakly to activins in LbT2 cells. The ovine Fshb promoter is induced by activin A but to a lesser extent than the rodent promoters. Interestingly, the canonical 8-bp SBE in the murine and rat promoters is absent in both human and sheep, suggesting that the differential activin responsiveness of the different species' promoters might reflect the presence/absence BERNARD AND TRAN of this cis-element. In support of this idea, introduction of the SBE into the human FSHB promoter increases its sensitivity to activin A as well as to overexpressed SMAD proteins [35, 77] . Miller and colleagues suggested that activin induction of the ovine Fshb promoter might be SMAD independent [78] . More recent data, however, challenge this idea and instead show roles for both SMAD3 and SMAD4 in activin A regulation of ovine Fshb promoter activity in LbT2 cells [79] . These data converged to support the hypothesis that activins signal via a canonical pathway in gonadotrophs to regulate Fshb transcription and that differential SMAD binding, in particular via the 8-bp SBE, might explain interspecies differences in activin sensitivity. However, as Thomas Huxley once said, ''The great tragedy of science [is] the slaying of a beautiful hypothesis by an ugly fact.'' In this case, the ugly fact presented itself in the form of a pig.
THE STORY OF THE PIG AND THE FOX
Rhodes and colleagues reported that the porcine Fshb promoter, which lacks the 8-bp SBE, is robustly stimulated by activins in LbT2 cells [34] ; indeed, even more so than the murine promoter [32] . Strikingly, the porcine promoter bears high sequence identity to the activin-insensitive human FSHB. A systematic comparison of the human and porcine promoters FIG. 1. Schematic representation of activin-regulated expression of the murine Fshb subunit. Dimeric activins bind to type II receptor serine-threonine kinases such as ACVR2A. Type I receptors, such as ALK4 or ALK7, are then recruited into the complex and trans-phosphorylated (denoted by a P in a circle) by the type II receptors. The activated type I receptors then phosphorylate and activate the intracellular signaling proteins SMAD2 and SMAD3. These SMADs partner with the co-SMAD, SMAD4, and accumulate in the nucleus. SMAD complexes regulate the promoter through different mechanisms. For example, SMAD2-SMAD3-SMAD4 bind an 8-bp SMAD-binding element (SBE) in the murine (m) or rat (r) promoters. SMADs also partner with the gonadotroph/thyrotroph-specific transcription factor FOXL2 to regulate Fshb transcription. FOXL2 can bind at least three different forkhead-binding elements (FBEs) in the murine promoter. Of these, the proximal FBE3 appears to be most critical. SMAD4 binds an adjacent SBE, and SMAD3, which interacts with both SMAD4 and FOXL2 via its C-terminal MH2 domain, links the proteins in a single complex. Whether SMAD2 participates in this complex is unresolved. FBE3 (shown in italics) is conserved in the porcine (p) and human (h) promoters. The relative position of the adjacent SBE (underlined) differs slightly between species. In the porcine Fshb promoter, a second FBE (corresponding to FBE2 in the figure) with an adjacent SBE (not pictured) is critical for its activin induction. The sequence of this FBE differs at one or two positions (underlined) between pig, human, and mouse. Whether FOXL2 actually binds this part of the murine promoter is unresolved. The third FBE (FBE1) is unique to the murine promoter. Though it binds FOXL2, it is unclear how and to what extent this site mediates activin induction of transcription. A conserved PITX-binding site also participates in the activin response, but its mechanism of action still requires refinement. [32] . In silico analysis further revealed a putative forkhead box (FOX) D1 cis-element, which included this bp (see bold T in FBE2 in Fig. 1 ) in the pig, but not human promoter. This was an intriguing discovery, as the first-described DNAbinding partner for SMAD proteins was another member of the forkhead box family, FOXH1 (formerly called FAST-1) [80, 81] . At the time, FOXD1 expression in gonadotroph cells had not been described, but earlier work by Ellsworth et al. [82] showed selective expression of another family member, FOXL2, in gonadotrophs (and thyrotrophs). Moreover, FOXL2 was implicated in the regulation of the GnRH receptor (Gnrhr) [83] . Given the similarity in cis-elements between many forkhead family members [84, 85] , we asked whether FOXL2 might differentially bind the human and porcine promoters and somehow mediate activin induction of the latter. Indeed, not only does FOXL2 bind the putative forkhead-binding element (FBE) in the porcine promoter more strongly than the corresponding sequence in the human promoter, but swapping the divergent base pairs between the two species completely reverses their activin responsiveness and FOXL2-binding activity [32] . In addition, depletion of endogenous FOXL2 in LbT2 cells impairs activin induction of the porcine Fshb promoter, whereas ectopic FOXL2 expression confers activin sensitivity to an otherwise unresponsive porcine Fshb promoter in heterologous cells. Collectively, these data indicate that activin stimulation of porcine Fshb promoter activity is FOXL2 dependent.
ACTIVIN REGULATION OF FSH
VIA FOXL2 identified a single bp difference between the two species, which appeared to explain their differential activin responsiveness
FOXL2 REGULATION OF FSHB TRANSCRIPTION: FOR PIGS ONLY?
Importantly, the defined porcine FBE is not only altered in the human FSHB promoter, but it is similarly modified in the murine, rat, and ovine Fshb promoters, all of which are activin responsive in LbT2 cells. This raised the question of whether FOXL2 regulation of Fshb promoter activity might be porcine specific; that is, just as the 8-bp SBE is unique to the rodent Fshb promoters, it was possible that the identified FBE and, by extension, FOXL2 might only be important for activin induction of the porcine gene. However, regulation of murine Fshb promoter activity also proved to be FOXL2 sensitive [32, 62] , suggesting that the protein might act via another ciselement (or elements). We identified an alternative, more proximal FBE (FBE3 in Fig. 1 ) that both binds FOXL2 and is critical for activin induction of murine Fshb transcription [62] . Importantly, this element is conserved across species, including rat, pig, and human. Thus, FOXL2 appears to act as a general regulator of Fshb transcription, but its underlying mechanisms of action might be both conserved and species specific. Consistent with this idea, Coss and colleagues identified at least two additional FOXL2 binding sites in the proximal murine Fshb promoter [37] , one corresponding to FBE2 and another more distal to the start of transcription (FBE1 in Fig.  1 ). Of the three sites, FBE3 appears most critical for activin induction of promoter activity [62] .
CLOSING THE LINK BETWEEN ACTIVIN SIGNALING AND FOXL2
If FOXL2 does indeed mediate activin-regulated Fshb transcription, how does it link to the activin-signaling cascade? Ellsworth et al. demonstrated an interaction between SMAD3 and FOXL2 using a mammalian two-hybrid system [83] . They further showed that the C-terminal Mad homology 2 (MH2) domain of SMAD3 and the forkhead (DNA-binding) domain of FOXL2 are critical for this association. Bilezikjian and colleagues confirmed these observations using coimmunoprecipitation analyses in HEK293 cells overexpressing epitopetagged forms of the proteins and further showed that FOXL2 interacts with SMAD3 but not SMAD2 or SMAD4 [86] (see also [87] ). The preferential interaction between FOXL2 and SMAD3 is somewhat surprising given the high sequence conservation between SMAD2 and SMAD3, particularly within their MH2 domains (97% identity). Additional work will be needed to understand the molecular basis of this preferential interaction. Nonetheless, these data place SMAD3 as a potential linchpin between activin signaling and FOXL2.
The SMAD-FOXL2 physical association is complemented by their functional cooperativity. SBEs (AGAC or GTCT) are located immediately adjacent to the two identified FBEs in the porcine Fshb promoter, and mutations to these sites either impair (site next to FBE3) or completely abrogate (site next to FBE2; not pictured in Fig. 1 ) activin A or SMAD3 induction of porcine reporters in both homologous and heterologous cells [87] . Both FOXL2 and SMAD3 must possess DNA-binding activity to stimulate the porcine Fshb promoter. These data suggest a mechanism whereby activins induce the nuclear accumulation of SMAD complexes that associate with FOXL2 (principally via SMAD3) and bind to adjacent SBEs and FBEs in at least two locations in the proximal porcine promoter. It is presently unclear whether FOXL2 constitutively binds to these elements or whether it is recruited upon activin signaling. However, SMAD3 binding (at least to the more distal SBE) requires prior or coordinated FOXL2 residency at the promoter [87] .
Similar, though not identical mechanisms, pertain to regulation of the murine Fshb promoter, which lacks the more distal composite SBE/FBE element observed in pig (FBE2 in Fig. 1 ). Perhaps as a result, mutations to the SBE in the more proximal composite element in mouse (SBE/FBE3 in Fig. 1 ) are significantly more damaging than in pig [62, 87] . Remarkably, they are also more disruptive than mutations to the rodent-specific 8-bp SBE [61, 62] . Similar to pig, the murine Fshb promoter can be synergistically regulated by SMAD3/4 in combination with FOXL2 in heterologous cells [62] . In contrast, however, this activity can be further potentiated by SMAD2 coexpression, and SMAD3 does not need to bind DNA directly provided that SMAD4 retains its DNA-binding activity. Collectively, these data suggest that FOXL2 and SMAD complexes cooperatively regulate Fshb transcription through composite cis-elements. However, the relative roles of individual SMADs and binding sites may differ between species.
A ROLE FOR FOXL2 IN FSH SYNTHESIS IN VIVO
Although the in vitro data strongly implicate FOXL2 in regulation of Fshb transcription, the in vivo role of FOXL2, if any, was unknown until recently. Global deletion of the single exon Foxl2 gene in mice causes both craniofacial defects and disruption of normal ovarian follicle development [88, 89] . Bilezikjian and colleagues reported that these animals are also FSH deficient [90] . Unfortunately, the poor health and viability of the mice restricted the analysis to relatively few animals, all of which were pre-or peripubertal. In addition, these animals display hypoplastic pituitaries and defects in hormone production by cell lineages that do not express FOXL2. Therefore, Foxl2 À/À mice may display a general impairment in pituitary development, though this does not rule out gonadotroph-specific effects of the gene deletion on FSH production.
BERNARD AND TRAN
To circumvent these confounding factors, we generated gonadotroph-specific Foxl2 knockout mice using a Cre/loxP strategy [91] . These animals develop into adulthood allowing a complete assessment of their reproductive physiology. Both male and female conditional knockouts (cKOs) are subfertile. Males exhibit decreased testis size and sperm counts, whereas female cKOs have smaller ovaries with a reduced number of corpora lutea when compared with controls. Both male and female cKOs have reduced serum FSH and pituitary Fshb mRNA levels, whereas Lhb mRNA synthesis appears normal. Both basal and activin A-stimulated Fshb mRNA expression are significantly reduced in primary pituitary cultures from cKO animals relative to controls. This is also the case in pituitaries from Foxl2 À/À mice [90] . Collectively, these data indicate that FOXL2 is an essential and selective regulator of FSH production in gonadotroph cells in vivo. Moreover, FSH deficiency in these knockout animals results, at least in part, from impaired activin regulation of Fshb expression.
Interestingly, in both Foxl2 knockout models, FSH synthesis is severely impaired but not completely absent. At present, the mechanisms underlying the residual Fshb expression are unknown. Certainly, it is possible that not all FSH synthesis is FOXL2 dependent. Because mutations to the FBEs in Fshb promoter-reporters are more damaging to transcriptional activity than is depletion of the FOXL2 protein in LbT2 cells [32, 62, 87] , it is possible that other forkhead proteins, particularly those with similar DNA-binding specificity and an ability to interact with SMAD proteins [43, 80, 81, [92] [93] [94] [95] [96] , might compensate for the loss of FOXL2. Nonetheless, the in vivo data clearly indicate that any such compensation is insufficient to maintain quantitatively normal FSH production and fertility.
A ROLE OF FOXL2 IN HUMAN FSH SYNTHESIS?
A currently unresolved issue is whether FOXL2 regulates human FSHB transcription and, if so, how. As indicated above, activins, when administered alone, poorly stimulate human FSHB promoter-reporters in LbT2 cells. However, activin A potentiates GnRH-stimulated FSHB reporter activity in these cells [97] . In addition, several clinical observations indirectly implicate activins in regulation of FSH secretion in humans (e.g., [98] [99] [100] [101] [102] [103] [104] [105] ). FOXL2 is expressed in human gonadotrophs [106, 107] and can bind to at least three elements in the proximal human FSHB promoter [37] . Two of these sites correspond to FBE2 (weak binding) and FBE3 (strong binding). The third site is about 220 bp upstream of the transcription start site and may be human specific [37] . In our experience, the human FSHB promoter-reporter is too weakly stimulated by activins or constitutively active type I receptors to assess the functional roles of these elements in LbT2 cells [35] . However, Coss and colleagues showed that mutations of two of these sites significantly impair both activin A and constitutively active ALK7 induction of the human promoter [37] . They did not examine a role for FBE3. Though these data are encouraging, more work is needed to firmly establish if and how FOXL2 regulates human FSHB.
More than 100 different FOXL2 mutations (.70% intragenic) have been reported in patients with blepharophimosisptosis-epicanthus inversus syndrome (BPES), a rare autosomal dominant disorder marked by eyelid malformations with (type I) and without (type II) premature ovarian failure (POF) [108] [109] [110] [111] [112] . POF is typically associated with elevated FSH as a result of decreased ovarian hormone negative feedback (e.g., [113, 114] ). To our knowledge, serum FSH levels have not been investigated systematically in women with BPES type I; however, FSH tends to be elevated in those cases where hormone measurements have been reported (e.g., [109, [115] [116] [117] [118] [119] [120] [121] ). At face value, this might suggest that FOXL2 is dispensable for FSH synthesis in humans. However, we would recommend a more nuanced and guarded interpretation of the available data.
Loss of function of both Foxl2 alleles is required to significantly impair FSH production in mice [91] . The majority of FOXL2 mutations in BPES cases, however, are heterozygous and are rarely associated with overt pituitary dysfunction. Therefore, gonadotrophs (and the FSHB promoter in particular) may be less sensitive to FOXL2 gene dosage than the developing eyelids or ovary, which in turn show differential sensitivities to alterations in FOXL2 abundance or function [122] ; that is, whereas all pathogenic FOXL2 mutations appear to cause eyelid malformations, it is only those that definitively impair FOXL2 expression, trans-activation function, and/or DNA binding (i.e., true loss of function mutations) that result in the ovarian dysfunction seen in BPES type I [123, 124] . Less damaging mutations, including some amino acid substitutions (both inside and outside of the forkhead domain) and expansions of a conserved polyalanine tract (most often from 14 to 24 residues), appear to cause more modest and genespecific effects on FOXL2 trans-activation function. Though strict genotype-phenotype relationships have not yet been established [125] , the existing data do allow one to propose a continuum of organ-or cell type-specific sensitivities to FOXL2 variants, wherein relatively mild mutations cause craniofacial defects, loss of function in one FOXL2 allele further causes POF (likely of ovarian origin), and, finally, loss of function in both alleles causes FSH deficiency (at least in mice).
To date, few homozygous mutations in FOXL2 have been described in humans. In one case [126] , the missense mutation, E69K, causes FOXL2 to form aggregates in the nucleus, but does not notably alter the protein's trans-activation function (on at least three promoter-reporters) [124, 127] . In another case [120] , an expansion of the polyalanine tract from 14 to 19 residues, which fails to cause BPES in heterozygous carriers, leads to mild cytoplasmic and nuclear aggregation of the mutant protein and does not impair trans-activation function [128] . Thus, the homozygous mutations identified thus far fail to cause complete loss of protein function. As a result, there are no human cases (yet described) analogous to the global or conditional Foxl2 knockout mouse models. Homozygosity for loss of function mutations in FOXL2 may be required to observe FSH deficiency in humans; however, such mutations may prove incompatible with viability as is the case in the majority of Foxl2 À/À mice ( [88] [89] [90] and our unpublished observations).
FUTURE PERSPECTIVES
The discovery of FOXL2 as a regulator of activin-stimulated FSH synthesis represents a major advance for the field, perhaps comparable in impact to the serendipitous finding of early growth response 1's (EGR1) role in GnRH-regulated LH production [129] . That said, many questions remain unanswered and we consider a few examples below.
1) Though FOXL2 acts as a mediator of activin signaling, might it play a more general role in hormonal regulation of Fshb/FSHB expression? In preliminary analyses, we did not observe effects of FBE mutations or Foxl2 knockdown on GnRH-stimulated porcine or murine Fshb promoter activity in LbT2 cells [32] ; however, more recent data implicate FOXL2 in progesterone-stimulated promoter activity [77] . Specifically, ACTIVIN REGULATION OF FSH VIA FOXL2 mutations of either FBE1 or FBE2 significantly impair a progestin's (R5020) independent and synergistic (with activin A) induction of murine Fshb promoter activity. FBE3 (at least as defined here) was not examined. Moreover, both isoforms of the progesterone receptor, which associate with SMAD proteins [56] , interact with FOXL2 and a dominant-negative form of FOXL2 inhibits R5020 induction of murine Fshb promoter activity. Clearly, more work is needed to establish the full extent of FOXL2's role in hormonal regulation of Fshb transcription.
2) Does FOXL2 play a more general role in cell-specific (basal) expression of Fshb/FSHB? Gonadotroph-specific and GnRH-regulated expression of the LHB/Lhb subunit depends on the coordinated activity of general (EGR1), organ-specific (paired-like homeodomain transcription factor 1, PITX1), and cell-specific (SF1) transcription factors [130] . The available data suggest that a similar complex may regulate Fshb/FSHB transcription, with FOXL2 functioning as an organ-or cellrestricted component therein; that is, SF1, which has been implicated in FSH synthesis [131] [132] [133] , can functionally and physically interact with FOXL2 [134] [135] [136] [137] . PITX1 and PITX2 (isoforms; [138] ) regulate basal and activin-stimulated FSHB/Fshb expression via a conserved cis-element in the proximal promoter [33, [139] [140] [141] ] (see Fig. 1 ). To our knowledge, functional and physical interactions between FOXL2 and PITX proteins have not been described, but it is notable that, like FOXL2, PITX1 and PITX2 interact with SMAD3 [139, 141] . In addition, PITX2 can interact with another forkhead protein, FOXC1 [142] , providing a precedent for association between members of these protein families. GATA2 has also been implicated in FSH regulation in vivo [143] , though its underlying mechanism of action is unknown. FOXL2's physical and/or functional interactions with each of these candidate partners as well as with novel proteins identified through unbiased screens [144, 145] warrant further investigation. Such analyses may provide needed insight into mechanisms restricting FSHB/Fshb expression to gonadotrophs.
3) How does FOXL2 actually regulate Fshb/FSHB promoter activity? Beyond DNA binding, there are few data from the literature that speak directly to this issue. Transcriptional activation and repression domains have been mapped in other forkhead proteins (e.g., [146] [147] [148] [149] [150] ). Given the lack of sequence identity among family members (outside of the DNA-binding domain), however, it is unclear how or if this informs our understanding of FOXL2 function. Because FOXL2 can both activate and repress transcription, depending on the target gene (e.g., [32, 82, 83, 86, [151] [152] [153] ), more mechanistic analyses are needed to determine whether or not the protein possesses inherent transcriptional regulatory domains. Some forkhead proteins regulate target gene expression through direct interaction with TATA-binding protein (TBP) and related factors [147, 154] . Because Fshb/FSHB contains a conserved TATA box within 30 bp of the transcription start site, FOXL2's association with the basal transcriptional machinery merits closer scrutiny. Transcription is associated with, if not dependent upon, chromatin remodeling, and forkhead proteins are known to recruit chromatin-modifying enzymes, including histone acetyltransferases (HATs), to target genes (e.g., [155] [156] [157] [158] ). Whether FOXL2 similarly interacts with HATs such as p300 or CBP has not yet been determined; however, SMADs 2, 3, and 4 regulate transcription through recruitment of these and other HATs (e.g., [159] [160] [161] [162] [163] ). Therefore, it will be important to determine whether FOXL2 recruits HATs (or other histone modifiers) to the Fshb/FSHB promoter either alone or in concert with SMADs or other cofactors. Indeed, with few exceptions (e.g., [164, 165] ), how hormones, signaling proteins, and transcription factors epigenetically regulate the Fshb/FSHB locus is virtually unknown and represents fertile ground for future investigation.
In summary, though activins were discovered as potent regulators of FSH synthesis more than a quarter century ago, it is only in the last few years that we have finally gained real insight into the underlying mechanisms. The recent discovery of FOXL2 as a critical mediator of activin-regulated Fshb transcription should serve as a catalyst for more in-depth investigations. The results of such analyses promise not only to advance our understanding of cell-specific and hormonally regulated gene expression, but may uncover novel targets for the treatment of infertility and other reproductive disorders.
